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A primary effusion lymphoma (PEL) is a fairly rare clinical variant of a non-
Hodgkin’s lymphoma (NHL) which usually occur in immunocompromised patients-
predominantly in human immunodeficiency virus (HIV)-positive individuals.
That are characterized by malignant effusions of serous body cavities where no
primary lymphoid tumor mass exists.
1-5 Human herpes virus (HHV)-8 is the most
common etiological factor found in association with this clinical entity. In this
case report, a patient with ascites and pleural effusion diagnosed as PEL is
presented, along with some extraordinary clinical features.
A 63 year old man with the complaints of progressive abdominal swelling, weight
loss and malaise was admitted. He had been taking oral anti-diabetic drugs for the
last 5 years but his previous history was otherwise noncontributory. The general
condition of the patient was moderate and his vital signs were as follows;
temperature: 36.8˚C, heart rate: 120/minand blood pressure: 100/60 mmHg,
respiration: 16/min. A physical examination revealed bilateral ralles, tachycardia,
deeper heart sounds and ascites without splenomegaly. No peripheric lym-
phadenopathy (LAP) was detected. A complete blood count yielded hemoglobin:
10.5 g/dL, hematocrit: 31-%, leukocytes: 9,600/mm
3, platelets: 210,000/mm
3 and
erythrocyte sedimentation rate (ESR): 86 mm/h. A peripheric smear disclosed
60% polymorphonuclear leukocytes, 30% lymphocytes, 8% monocytes, normo-
chrome and normocytic red blood cells. The other laboratory tests were as
follows: blood glucose: 229 mg/dL, total protein: 5.3 g/dL and  albumin: 3.2 g/dL,
with normal liver and renal function tests. Hepatitis markers and anti-HIV were
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INTRODUCTION
CASE REPORTnegative, but he was Epstein-Barr virus (EBV) immu-
noglobulin (Ig) G positive. Serum protein electrophoresis
was normal but with low albumin level. Tumor markers
were negative but the cancer antigen-125 (Ca-125) was >
500 U/mL. Posterior-anterior chest radiography depicted
left pleural effusion. The echocardiography was normal
but with minimal pericardial effusion. Abdominal ultraso-
nography demonstrated massive ascites and upper gastro-
intestinal tract endoscopy detected an active gastric ulcer
in the cardia. A biopsy specimen from the lesion was
relevant with regenerative hyperplasia. The onward com-
puterized tomography of the thorax and abdomen demons-
trated bilateral pleural effusions and pronounced ascites-
but neither organomegaly nor LAP. The aspirated material
from the ascites was exudative and direct microscopy
uncovered atypical lymphomononuclear cells without any
tuberculous bacilli (Fig. 1). The adenine deaminidase level
was < 200 U/L. A bone marrow biopsy was normal but
hypocellular. During the follow up, thoracentesis and
paracentesis were performed as the patient had progressive
dyspnea and a cytological analysis of both fluid materials
displayed a high grade malignant lymphoma. The immune
phenotype analysis by flow cytometry was consistent with
B-cell predominant NHL with kappa monoclonality (Table
1). The levels of interleukin (IL)-6, IL-10 and HHV-8
were not studied due to laboratory insufficiency.
Overall, the patient was diagnosed as PEL and a further
laparoscopic peritoneal biopsy was planned. This however
could not be accomplished due to the worsening general
conditioning of the patient. A CHOP chemotherapy pro-
tocol (cyclophosphamide 750 mg/m
2, adriamycine 50
mg/m
2, oncovine 14 mg/m
2 on day 1 and prednisolone 100
mg on days 1-5, repeated every 21 days) was applied. The
patient’s general condition improved, both the pleural
effusion and ascites regressed in a one week period. The
ESR declined to 24 mm/h and the patient was discharged
with an appointment for the second cycle of chemothe-
rapy. The second cycle was given on an outpatient basis
thereafter the remaining protocol could not be sustained
due to the patient’s untoward hematological status. The
patient died in the fifth month following diagnosis of
progressive ascites and dyspnea.
Due to its distinct biological and clinicopathological
features, PEL has been recognition as an independent
lymphoproliferative malignancy -with a large cell mor-
phology, B cell genotype and tendency to infiltrate serous
mucosa causing effusions without any tumoral mass or
LAP.
1,4,6-8 More specifically, it is defined as a lymphoma of
the post-germinal center, pre-terminally differentiated B-
cells.
2 PEL became salient around 1995, after which there
has been much effort to clarify its -yet uncertain- obscure
pathogenesis. By and large, HHV-8 and EBV are the
leading suspective etiological factors.
1-5 HHV-8, also
termed as Kaposi’s sarcoma (KS)-associated herpes virus,
4,9
is a gamma herpes virus which encodes genes highly
homologous to cytokine genes and genes closely related to
cell cycle control.
4,9,10 According to experimental studies,
HHV-8 is also found to induce acceleration of the cell
cycle and cell transformation or promote the proliferation
of infected cells.
11,12 HHV-8 DNA is rarely found in
various tumor and non-tumor tissues from patient groups
not at risk of KS whereas it has been shown to be in
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DISCUSSION
Fig. 1. Atypical lymphoid cells with (A) features of abundant mitotic figures,
pleomorphism, basophilic cytoplasm with clear vacuoles and prominent nucleoli
(MGG ×40) and  (B) features of pleomorphism and multinucleation (MGG ×40). 
B
A
Table 1.Flow Cytometry from the Peritoneal Fluid
Antigen % Antigen %
CD 45 99 CD 20 97
CD 14 9 CD 103 11
HLA-DR 98 CD 11c 28
CD 22 95 CD 44 83
CD 5 10 CD 54 91
CD 19 95 Kappa 90
CD 25 11 Lambda 8
CD 23 26 cBCL 2 46
CD, cluster of differentiation; BCL, Burkit cell line (Bcl-2).exclusive association with KS, multicentric Castleman’s
diseaseand PEL but less so with multiple myeloma and
sarcoidosis.
3,5,13,14 
Despite the skepticism of its role in the pathogenesis of
PEL, aconcurrent EBV infection takes place in approxima-
tely 70% of patients.
4 It is also speculated that a patholog-
ical synergy exists between EBV and HHV-8 in the
pathogenesisof PEL. In contrast to HIV-positive patients
who are usually also EBV-positive, almost all HIV-
negative cases with PEL are EBV-negative.
5 Interestingly,
EBV IgG was positive in our patient.
PEL is usually observed in patients with acquired immune
deficiency syndrome (AIDS) or other forms immuno-
compromisation.
15 Although very rare, the clinical scenario
of PEL, When it occurs in immunocompetent patients, is
different comprising old age, normal immunity, less EBV
co-infection and apparently a less aggressive disease
course.
8 The precise mechanism of PEL occurring in
healthy individuals with normal immunity can not be
elucidated whereas aging, decreased T cell immunity with
normal or increased humoral response are few of the
proposed mechanisms.
4,8 Extraordinarily, our patient was
relatively younger than the HIV-negative males hitherto
mentioned in the literature,
5,8 with EBV IgG positivity and
an aggressive clinical course.
The diagnosis of PEL is usually established with relevant
clinical evidence-effusions with tropism for the serous
cavities and inconclusive attempts of demonstrating any
primary lymphoid tumoral mass and with further analysis
of the fluid material by either immunohistochemistry or
flow cytometry. Moreover, genetic analysis for the presence
of HHV-8 and EBV DNAs can additionally strengthen the
diagnosis. Similarly to our patient, the serum Ca-125 level
can anecdotally be high in some cases due to an inflam-
matory serosal reaction.
16
The prognosis of PEL is usually poor and the majority
of the patients die with in one year of diagnosis.
3,7 The
effusions can temporarily be kept under control despite
various chemotherapy protocols such as CHOP.
3,9,17
Our HIV-negative male patient relatively younger than
the aforementioned patients in the literature with normal
immunity but EBV IgG positivity and an aggressive clinical
course exemplifies a somewhat extraordinary clinical
scenario, per se, of such a rare pathology. Herein, we also
orient the clinicians towards being vigilant about PEL -vis-
a-vis the differential diagnosis of ascites.
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